Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018 MONOVISC and CINGAL Global Revenue Increased 14% for Full Year of 2018 BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 21, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 7, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2018 financial results after the close of the market on Thursday, February 21, 2019 and hold its investor conference call on the
BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 16, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase HYALOFAST , a
BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 12, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced plans to showcase its entire
Company Expands HYALOFAST Commercial Reach in Asia , the Middle East and Latin America BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 4, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
Long-Serving Director Steven Wheeler to Retire from Board in February 2019 BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 10, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day,
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief
